Recommendation applies across England and Wales and the treatment is available now
Otsuka Pharmaceuticals has revealed that the National Institute for Health and Care Excellence (NICE) has recommended Lupkynis in combination with mycophenolate mofetil (MMF).
The treatment has been developed as a therapy for adults with active lupus nephritis (LN) class 3, 4 or 5 – including mixed class 3/5 and 4/5 – when provided as a commercially arranged patient access scheme…
